In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Shares of Pfizer Inc. PFE shed 2.42% to $25.86 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.02% to ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer (PFE) closed the most recent trading day at $26.50, moving +2.4% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. At the same time, ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product ...